Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.
Hum Vaccin Immunother
; 20(1): 2309701, 2024 Dec 31.
Article
en En
| MEDLINE
| ID: mdl-38299612
ABSTRACT
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) require additional treatments, especially those not eligible or not responding to high dose cytotoxic chemotherapy and stem cell transplantation. Over the last few years, several new treatments have been developed and approved for these patients, among them of particular relevance are those targeting CD19. Tafasitamab is a humanized monoclonal antibody targeting CD19, composed of a modified fragment crystallizable (Fc) region engineered with higher affinity for Fc gamma receptors (FcγR) receptors, leading to increased cytotoxicity through natural killer cells and macrophages (antibody-dependent cellular cytotoxicity and antibody-dependent cell-mediated phagocytosis). In this product review, we will discuss its mechanism of action, safety profile and efficacy results from clinical trials that led to its approval in combination with lenalidomide for patients with R/R DLBCL ineligible for high-dose chemotherapy and autologous transplantation.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Linfoma no Hodgkin
/
Linfoma de Células B Grandes Difuso
/
Antineoplásicos
Tipo de estudio:
Etiology_studies
Límite:
Humans
Idioma:
En
Revista:
Hum Vaccin Immunother
/
Hum. vaccin. immunother. (Online)
/
Human vaccines & immunotherapeutics (Online)
Año:
2024
Tipo del documento:
Article
País de afiliación:
Suiza